Immunome Inc. (IMNM) research
Immunome Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $24.24
- As of
Immunome Inc. (IMNM): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-11.
As of . Source: SEC EDGAR filings for IMNM. Method and limitations.
Share the IMNM intelligence card
See IMNM live in the terminal
Track IMNM's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live IMNM terminal, freeActive signals for IMNM
- highCONSENSUS_BUY
3 tracked funds increased IMNM this 2026Q2, institutional consensus
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 22.0%, EPS $-0.65 vs $-0.5326 estimate
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +264% to IMNM (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 69% of IMNM (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +224% to IMNM (2026Q2)
FREE, NO ACCOUNT
Every signal on IMNM, as it fires
You are seeing 5 of 23 signals recorded on IMNM since 2026-05-17.
The five above landed across 3 days. The other 18 were recorded on 4 other days. 16 of the 23 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in IMNM (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 45257U108 · 2026Q2 | $5.3M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 45257U108 · 2026Q2 | $4.7M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 45257U108 · 2026Q2 | $507K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, IMNM
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
IMNM against its peers
IMNM's operating margin of -3228.8% ranks in the 16th percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-11-30 and 2025-12-31.
| Metric | IMNM | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 6.9M USD | 77.4M USD | 21 | 16 |
| Operating margin | -3228.8% | -340.2% | 16 | 15 |
| Net margin | -3060.0% | -314.9% | 16 | 15 |
| Return on equity | -33.5% | -47.4% | 60 | 23 |
Peers (24): ATAI, PHVS, PGEN, ZLAB, NAMS, NRIX, IRON, MLYS, ARQT, MBX, QURE, VRDN, CLDX, VERA, BEAM, RCUS, VCYT, SLS, DNLI, AUPH, BCRX, SRPT, DYN, PVLA. Left out: ZLDPF (no annual filing). Fiscal periods ending between 2025-11-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (IMNM: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more IMNM signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to IMNMand get the insider, 13F, options, and confluence read in one view.